EnsiliTech utilizes a patented ensilication process to encase thermally unstable biomolecules within a silica network for enhanced stability. This technology eliminates the need for cold-chain logistics for vaccines, antibodies, and diagnostics, preventing spoilage and extending shelf-life across a wide temperature range. The method supports both new and existing biopharmaceutical formulations without relying on lyophilization or harsh processing conditions.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TFFounders
Product
Problem
A significant percentage of vaccines and biological materials are wasted globally due to failures in cold chain transport and storage, resulting in financial losses and limiting access to critical therapeutics and diagnostics, especially in regions with unreliable infrastructure. The reliance on refrigeration for biomolecule preservation contributes significantly to vaccination program emissions and overall environmental impact.
Solution
EnsiliTech has developed a patented ensilication method that encases thermally unstable biomolecules within a silica network, protecting them from degradation at temperatures between -80°C and +50°C. This technology eliminates the need for cold-chain logistics, improving the shelf-life and global accessibility of biological therapeutics and diagnostics. The ensilication process does not rely on lyophilization or other harsh conditions, making it suitable for both existing and new biopharmaceutical formulations. By preventing spoilage and reducing reliance on energy-intensive cooling, EnsiliTech aims to reduce costs and environmental impact associated with the transportation and storage of biological materials.
Target Audience
The primary target audience includes biopharmaceutical companies, vaccine manufacturers, research institutions, and healthcare organizations seeking to improve the stability, accessibility, and cost-effectiveness of their biological products.
Features
- Patented ensilication technology for encasing biomolecules in a protective silica network.
- Thermal stability of biomolecules between -80°C and +50°C.
- Elimination of cold chain requirements for transport and storage.
- Compatibility with a wide range of biomolecules, including antibodies, vaccines, and genetic material.
- Preservation of biological activity without harsh conditions like lyophilization.
- Potential applications in human and animal therapeutics, diagnostics, and laboratory research.